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a b s t r a c t
The outer-domain core of gp120 may serve as a better HIV vaccine immunogen than the full-length
gp120 because of its greater stability and immunogenicity. In our previous report, we introduced two
disulfide bonds to the outer-domain core of gp120 to fix its conformation into a CD4-bound state, which
resulted in a significant increase in its immunogenicity when compared to the wild-type outer-domain
core. In this report, to further improve the immunogenicity of the outer-domain core based immunogen,
we have introduced a Tryptophan residue at gp120 amino acid sequence position 375 (375S/W). Our data
from immunized guinea pigs indeed shows a striking increase in the immune response due to this stabi-
lized core outer-domain. Therefore, we conclude that the addition of 375W to the outer-domain core of
gp120 further stabilizes the structure of immunogen and increases the immunogenicity.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The CD4-binding site (CD4-BS) of gp120 in HIV-1 has been rec-
ognized to be the most vulnerable site for antibody targeting and
viral neutralization [1–8]. Recently, identification of several potent
neutralizing antibodies through the screening of HIV-1 patient
sera, such as VRC01 [9] and PGV04 [5], have been known to be eli-
cited by the CD4-BS of gp120. Further analysis of these antibodies
has found that the binding sites for some CD4-BS antibodies pri-
marily depend on the outer domain of gp120, which are unlike
CD4 binding wherein the binding requires all the three domains:
outer domain, inner domain and the bridging sheet [10]. It is
known that the outer domain is relatively more stable than the
inner domain, and the outer-domain core structure, which does
not include the V3 loop, is even more stable [11,12]. An optimized
outer domain from a HIV-1 subtype A strain can bind to the CD4-BS
antibodies VRC01 and PG04. The outer domain structure in com-
plex with PG04 has been also solved [13]. The outer domain used
as an immunogen has been tested for its immunogenicity previ-
ously, and it shows a comparable immune response to gp120,
but a weaker response than the gp140 envelope trimer. However,
it is an un-stabilized wildtype outer domain in which the
V3-loop and the glycan site (antibody 2G12) were focused, not
the CD4-BS [14]. A membrane anchored-outer domain is
recognized by antibody b12 and is also found to have elicited
CD4-BS antibodies [15]. All of these previous studies are based
on the wildtype outer-domains, but the outcomes have provided
the feasibility for developing outer-domain based immunogens.
CD4 binding to gp120 causes a large scale conformational
change of gp120 which involves the gp120 core structure and
the transitions of inner-domain layers (layer 1, 2 and 3), but also
involves the movement of the major loops (V1, V2 and V3)
[16–19]. For instance, the V2-loop joins the bridging sheet forma-
tion with the C4 region b20-b21 hairpin of the outer-domain, and
the V3-loop opens up to contact the coreceptor, CCR5 or CXCR4
[17,18,20]. A tryptophan residue at amino acid position 375
(375W) of gp120 will fill the Phenylaniane-43 (Phe-43) cavity
and stabilizes the gp120 into a CD4-bound conformation, but does
not completely achieve the CD4-bound state [21–23]. More stabi-
lization changes such as the addition of disulfides, salt-bridges
added to the S375W conformation of the gp120 core structure have
enhanced the stability and increased the immunogenicity [22,24].
However, in respect to the outer-domain core structure only, we
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do not know whether the 375W can play a role in further improv-
ing the stability of the CD4-bound state. Here we have conducted
the research into an outer-domain based HIV immunogen design.
The antigenic nature of the CD4-BS has been recognized as confor-
mation dependent because it is known to be located at the junction
of three domains. Interestingly, the binding sites of some CD4-BS
antibodies such as VRC01 or PGV04 are actually located on the
outer domain, and the binding is almost independent from the
inner domain and the bridging sheet. Since the outer-domain of
gp120 is a relatively stable domain, it has become an ideal anti-
body target for vaccine immunogen design.
In our previous study, a stabilized outer-domain, through the
introduction of two-disulfide bonds, was significantly more
immunogenic than the wild-type outer domain. To further
improve this outer-domain based immunogen, we have introduced
a Tryptophan (W) mutation at the position 375, which is known to
be the Phe-43 cavity filling residue in the CD4-BS. We expect that
the 375W will further stabilize the outer-domain into the
CD4-bound conformation in addition to the two-disulfide bond
stabilization. Thus, it will serve as a better immunogen to induce
the production of CD4-BS neutralizing antibodies.
2. Materials and methods
2.1. Outer domain OD3 mutagenesis
The outer domain mutant 3 (OD3) of HIV-1 gp120 from subtype
C strain 1084i essentially was designed based on the outer domain
mutant 2 (OD2) structure as described previously [25]. The S375W
mutation was introduced by Site-directed mutagenesis using the
mutagenesis kit from Agilent. The sequences of the mutations were
confirmed by DNA sequencing. The models of the OD1, OD2 and
OD3 structures were predicted based on the gp120-VRC01 struc-
ture complex (PDB: 3NGB) from an HIV-1 subtype B strain, and
conducted using Discovery Studio Client 4.0 (Biovia, San Diego,
CA). The protein sequence numbering of OD1, OD2 and OD3 is
based on the envelope sequence of the HIV-1 prototypic HXBc2
strain [26].
2.2. Cloning and expression of OD1, OD2 and OD3
The molecular clones of OD1 and OD2 were made during previ-
ous work [25], and the OD3 mutant was generated by mutagenesis
in the vector pET28b (Novagen). To express the recombinant pro-
teins in E. coli BL21 (DE3) pLysS cells (Invitrogen), the pET28b-
OD1, OD2 or OD3 plasmids were transformed into the cells and a
single colony was grown overnight in LB media supplemented with
kanamycin (50 mg/L) at 37 C until the optical density (OD)
reached between 0.4 and 0.6 at 600 nm. The cells were then
induced by addition of isopropyl-D-thiogalactopyranoside (IPTG)
at a final concentration of 1 mM and were further incubated for
4 h at 37 C. The cells were then harvested by centrifugation at
5000g for 10 min, washed once with STE buffer (100 mM NaCl,
10 mM Tris, and 1 mM EDTA, pH 7.5) and finally resuspended in
STE buffer containing 0.5% NP40, lysozyme (100 mg/L) and supple-
mented with protease inhibitors. After incubation for 30 min at
4 C, the resuspended cells were disrupted by sonication and the
lysate was centrifuged (12,000g, 10 min, 4 C) to separate the insol-
ubilized fraction. Both the supernatant and the insolubilized pellet
fraction were tested for the presence of recombinant proteins by
running SDS-PAGE followed by Coomassie blue staining. The
majority of the expressed protein was detected in the insolubilized
fraction of inclusion bodies. The insoluble fraction was further
purified by sequentially washing with 1x PBS containing 2 M urea,
0.1% SDS, 1% NP-40 and 1% TritonX-100, and was solubilized in sol-
ubilization buffer (50 mM NaCl, 25 mM Tris (pH-8.0), 2 mM EDTA,
8 M Urea and 5 mMDTT). The protein was finally renatured by suc-
cessive dialysis against refolding buffer (50 mM Tris, pH 8.0,
400 mM L-Arginine, 2 mM EDTA, 10 mM DTT and 10% glycerol)
containing 4, 2, 1 and 0 M Urea at 4 C. Ni-NTA resin beads
(Thermo Scientific) were used to further purify the protein. The
concentrations of the protein samples were determined by a BCA
protein kit (Pierce). The protein samples were finally evaluated
by Coomassie blue staining and Western blotting.
2.3. Western blot assay
Purified protein samples were loaded onto a 10% SDS-
denaturing gel along with negative (bovine serum albumin
(BSA)) or positive (recombinant gp120) controls. The gels were
run for 75 min at 60 V. Nitrocellulose membrane transfer followed
SDS-PAGE. After 30 min of blocking with 5% non-fat dry milk in
phosphate-buffered saline (PBS), nitrocellulose membranes were
incubated for one hour at room temperature with primary antibod-
ies. Following six washing steps (five minutes each) with PBS
+ 0.1% Tween-20, horseradish peroxidase (HRP) conjugated sec-
ondary antibodies were incubated with membranes for 30 min at
room temperature. Six washes were followed as previously
described. The outcome of antigen-antibody binding was detected
either using SuperSignal West Dura Extended Duration Substrate
kit (Pierce) or using a BioRad ChemiDoc.
2.4. Circular Dichroism (CD)
A desalting column (zebaTM Spin Desalting Columns, 7 K MWCO,
5 mL) was used to remove L-arginine from the protein solution to
avoid noisy signals. A Jasco J-815 CD spectrophotometer equipped
with Peltier-type thermostat in the cuvette holder and a water
circulator was used to collect the data. The acquisition and data
analysis software are also from Jasco. Data were recorded using a
0.01 cm pathlength, 1500 mL circular quartz cuvette at 20 C. The
data were exported in XY asci format and analyzed with the pro-
gram CD-Pro located at the Dichro Web-site from the University
of London, for the purpose of estimation of the secondary structure
of the protein. The data were converted to molar ellipticity
(degcm2dmol-1) from raw machine units (millidegrees) with the
same resolution as the acquired data (1 data point per nanometer).
The cell path, average molecular weight and protein concentration
were provided prior to the fitting, which was carried out using the
various models available (CONTINLL and SELCON3 yielded the low-
est RMSD values) until a satisfactory fit was obtained. The results
were imported into Sigmaplot (SPSS), which was used to plot the
data along with the simulated secondary structure spectrum. The
three protein samples were measured at the same concentration
of 0.35 mg/ml, solubilized in buffer containing 20mmTris-HCl and
2 mm EDTA at pH 8.0, and the recording path-length is 0.01 cm.
2.5. Guinea pig immunizations
The standard 63-Day immunization protocol of Cocalico Biolog-
icals, Inc. (CBI) for guinea pigs was followed. 16 guinea pigs were
assigned evenly into 4 groups: inoculated with OD1, OD2, OD3 or
adjuvant only (Complete Freund’s Adjuvant for initial inoculation,
but Incomplete Freund’s Adjuvant for boosters). Three booster
inoculations by Subcutaneous (s.c.) injections were carried out fol-
lowing the first injection. Blood samples were collected from all
guinea pigs on Day 0, prior to immunization as pre-bleed samples;
on Day 35 as test bleed samples after 2 boosts on Day 14 and Day
21, respectively; and on Day 63 as exsanguination samples follow-
ing the third boost on Day 49. Blood samples collected (pre-bleeds,
test bleeds and final bleeds) were used in antibody testing, ELISA
and neutralization assays. All animal experiments were performed
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according to the protocol approved by the IACUC of CBI (Ream-
stown, PA) (see Table 1).
2.6. ELISA
Flat-bottom with low evaporation lid 96-well plates (FalconTM)
were coated with 200 ng per well of the testing protein antigens
(OD1, OD2 or OD3) diluted in coating buffer (15 mM Na2CO3 and
35 mM NaHCO3, pH 9.6). Prior to blocking, plates were washed
with phosphate buffered saline with 0.1% Tween-20 (PBS-T,
Sigma-Aldrich) 3 times. Plates were blocked with 200 lL/well
blocking buffer (PBS-T with 5% milk) at room temperature for
1 h. After 3 washes with PBS-T, 100 lL/well of guinea pig sera
diluted in PBS-T to different ratios was added and incubated at
room temperature for 2 h. Plates were washed 5 times prior to
the addition of 100 lL/well of HRP-conjugated goat anti-guinea
pig IgG secondary antibody (Jackson ImmunoResearch Laborato-
ries Inc.), and incubated at room temperature for 2 h. Plates were
washed 5 times, and 100 lL/well SureBlue Reserve TM TMB sub-
strate (KPL) was added and incubated for 1 min in the dark.
100 lL/well of 1 M HCl was added to stop the reaction. Absorbance
data was collected at 450 nm using an ELX 800 UV universal micro-
plate reader (Bio-Tek Instruments).
2.7. Production of pseudotyped HIV viruses
HIV-1 isolates used for neutralization assay were pseudotyped
HIV-1 viruses produced by transfection of 293T cells with three
plasmids: pHIV-1-luc, pCMVGag-Pol, and pSVIIIenv of different iso-
lates. Transfection of these three plasmid produces luciferase-
expressing HIV-1 isolates in 293T cells after a three day incubation
period. Transfected 293T cells were grown at 37 Cwith 5% CO2, and
maintained in DMEM medium with 584 mg/L L-Glutamine (Gibco),
supplemented with 10% FBS and 1X penicillin-streptomycin.
Twenty-four hours prior to transfection, 1.5  106 cells were plated
in 10 cm dishes. Cells were transfected by adding 6 mg of
replication-deficient HIV-1 luciferase plasmid pHIV-1-luc, 2 mg
HIV-1 envelope construct pSVIIIenv-YU2/1084i/89.6/JRFL/HXBc2/
ADA, and 2 mg CMV backbone plasmid diluted in 1 mL unsupple-
mented DMEM. Polyethylenimine (PEI) was the transfection
reagent used in these experiments. Cell supernatantswere collected
at 72 h post-transfection, and were purified through a 0.45 mM syr-
inge tip filter. The amount of virus in the supernatants was mea-
sured by reverse transcriptase (RT) assay [27]. Viruses harvested
from the supernatant of the culture media were stored at 80 C.
2.8. Viral neutralizing assay
The viral neutralization assay was based on methods previously
described [28,29]. In brief, TZM-bl cells were incubated at 37 C
with 5% CO2, and maintained in DMEM medium with 4.5 g/L
D-glucose and 584 mg/L L-Glutamine, supplemented with 10%
FBS and 1X penicillin-streptomycin. One day prior to infection,
cells were seeded at 1.5  104 per well in flat-bottom, black-
sided 96-well plates (Grenier Bio-One). In a separate 96-well plate,
heat-inactivated guinea pig serum was serially diluted to a final
volume of 150 lL cell growth media, mixed with 50 lL cell growth
media containing 2500 RT units of pseudotyped HIV, and
incubated for 1 h at 37 C with 5% CO2. During this incubation,
TZM-bl growth media was replaced with 50 lL media containing
160 lg/mL DEAE-Dextran (Sigma-Aldrich) (40 lg/mL final concen-
tration). The serum-virus mixture was added to cells and incubated
at 37 C for 48 h. The luciferase assay system (Promega) was used
to detect Tat-inducible luciferase; luminescence was measured on
a Veritas Luminometer (Turner Biosystems). Percent neutralization
was determined as described previously [25].
2.9. Statistical analyses
All data statistical analyses were performed using Graphpad
Prism (v. 6.0). The statistical significances were determined by
using the Holm-Sidak T-test method [30,31]. To determine the
statistical significance of the antibody titers between day 0 and
day 35, or day 0 and day 63, statistical significance analysis was
conducted with alpha = 5.000% (Fig. 6A). To determine the statisti-
cal significance of the antibody titers between OD1 and Adjuvant,
OD2 and Adjuvant, OD3 and Adjuvant, OD1 and OD3, and OD2
and OD3, the Holm-Sidak T-test method was used with
alpha = 10.000% (Fig. 6B). To determine the statistical significance
of the virus-specific neutralizing activities between OD1 and
Adjuvant, OD2 and Adjuvant, OD3 and Adjuvant, OD1 and OD3,
and OD2 and OD3, the Holm-Sidak T-test method was used with
alpha = 5.000% (Fig. 7A).
3. Results
3.1. Structure-based design of the outer-domain into the CD4-bound
conformation
Based on the X-ray crystal structure of gp120 in the CD4-bound
conformation (PDB: 3NGB) [11], we have separated the outer
domain from the gp120 structure to design the immunogen. As
indicated in our previous work, we introduced two-disulfide bonds
to stabilize the outer-domain to maintain the CD4-bound confor-
mation (OD2) to generate targeted CD4-BS antibodies. In this
research, we have further improved the CD4-bound conformation
of OD2 by adding an additional serine to tryptophan mutation at
position 375 (S375W). The rationale for this design is based on
the previous finding that 375W is a Phe-43 cavity filling residue
in the gp120 structure which can stabilize the gp120 into the
CD4-bound conformation [11,21]. It was assumed that this 375W
mutation would further improve the OD2 conformation into the
CD4-bound state, which is the ideal conformation to be achieved
for vaccine design against the CD4-BS. The wild-type outer domain
(OD1), the two-disulfide stabilized outer-domain (OD2) and the
added S375W substitution outer-domain (OD3) are all shown
below in Fig. 1, including their structural models and the protein
sequences. In this research, we have purified the outer domain pro-
teins and compared them side-by-side through molecular charac-
terization and immunization. As in our previous study on OD2,
we have focused on an HIV-1 subtype C strain (1084i) that was
originally isolated from Zambia [32]. The 3-dimensional structure
model of 1084i gp120 was established during the previous study
using a molecular modeling approach. One disulfide serves to sta-
bilize the N- and C-termini of the outer domain as they are located
closely to the antibody VRC01 binding site. The other disulfide was
added to fix the b20/21 hairpin in the CD4-bound conformation,
which is favorable for VRC01 antibody binding (Fig. 1). Because this
Table 1
Immunization schedule.
Day Procedure Antigens and Adjuvant (CFA&IFA)a
0 Pre-bleed
Initial inoculation 200 mg antigen/animal with CFA
14 1st Boost 100 mg antigen/animal with IFA
21 2nd Boost 100 mg antigen/animal with IFA
35 Test bleed
49 3rd Boost 100 mg antigen/animal with IFA
63 Final bleed
a CFA, Complete Freund’s Adjuvant; IFA, Incomplete Freund’s Adjuvant.
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design focused specifically on the VRC01 binding site in the core
structure of gp120, the V1V2 loops along with the V3-loop were
removed. It is anticipated that these modifications will make this
immunogen more rigid as the CD4-bound conformation is sup-
posed to elicit potent neutralizing antibodies like VRC01 and PG04.
3.2. Characterization of the outer domain immunogens
The designed and synthesized immunogen genes OD1, OD2 and
OD3 were cloned into the pET28b vector (Novagen) to express the
proteins in E. coli BL21 (DE3) pLysS cells (Invitrogen). The proteins
Fig. 1. Models of the three designed immunogens (upper panel) and their amino acid sequence alignment (lower panel) are made using Discovery Studio and the sequence is
from the envelope glycoprotein gp120 of HIV-1 subtype strain 1084i. The outer domain (OD) is cut-off from position 254 of the full length gp120 molecule, which corresponds
to position 1 of the outer-domain numbering in this diagram. The protein sequence numbering is based on the full length sequence of gp120 standard numbering system [26],
but sequence numbers the for the outer-domains only are also indicated in the sequence alignment and in the brackets for the mutations: Dis-1, disulfide bond-1, T/C257-G/
C472 (T/C4-GC185); Dis-2, disulfide bond-2, E/C370-N/C425 (E/C97-N/C139); S375W (S102/W). OD1, wild-type outer domain; OD2, with two disulfide-bonds; OD3, with
two-disulfide-bonds plus S375W mutation.
M     OD2        OD3
IPTG +      - +      -
M   OD2    OD3 M   OD1  OD2  OD3
25 KDa
A. Coomassie blue 
(crude in E. coli)
B. Western blot
( nti-His-tag) 
C. Coomassie blue 
(Purified proteins)
Fig. 2. Protein expression and western blot verification. (A). Coomassie blue staining to evaluate the OD2 and OD3 protein expressed in E. coli BL21 (DE3) pLysS cells which
were induced by 1 mM IPTG. (B). Western blot of OD2 and OD3 protein using anti-His tag antibody. (C). Purification of OD1, OD2 and OD3 protein immunogens from the
Nickel column, and with the Coomassie blue staining. Note that the OD1 protein was purified from previous work in the laboratory.
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were characterized by SDS-PAGE, followed by Coomassie blue
staining (Fig. 2A). The induced protein bands were detected in
the Coomassie gel as expected the molecular weight of 25 kDa,
representing the outer domain proteins of HIV 1084i gp120, and
were also confirmed by Western blot using an antibody against
His-tag (Fig. 2B). Large amounts of OD1, OD2 and OD3 protein were
then prepared and purified via Ni-column for use in immuniza-
tions. After purification, the OD1, OD2 and OD3 proteins were fur-
ther checked for the purity by SDS-PAGE using Coomassie blue
staining (Fig. 2C). Clear bands of OD1, OD2 and OD3 confirmed
the high purity of these immunogen proteins. Some gp120-
specific monoclonal antibodies were also used to test the immuno-
gen conformation and recognition by CD4-BS antibodies. As
expected, the CD4-BS antibody VRC01 showed strong affinity to
OD1, OD2 and OD3, and the antibodies F105 and b12 also showed
positive binding. The CD4-induced (CD4i) antibody 17b also bound
to the immunogen proteins (Fig. 3). Note that some minor weak
unspecific bands present in the patient sera and VRC01 gels in
Fig. 3 are assumed to be gp120 dimers. The outer-domain glycan
dependent antibody 2G12 binding was negative (data not shown)
F105Anti-gp120 17bVRC01 b12Patient Sera
OD1  OD2  OD3   BSAOD1  OD2  OD3  BSAOD1  OD2  OD3  BSA OD1  OD2  OD3   BSA OD1  OD2  OD3   BSAOD1  OD2  OD3   BSA
25 KDa
CD4-BS antibody
Fig. 3. Characterization of the three immunogens by Western blotting. After SDS-PAGE and membrane transfer, protein samples of OD1, OD2, OD3 and BSA were probed with
pooled serum from HIV-1 positive patients, an anti-gp120 polyclonal antibody, CD4-BS monoclonal antibodies VRC01, F105, b12, and a CD4-induced monoclonal antibody
17b.
OD1 (%) OD2 (%) OD3 (%)
Helix1 14 16 17
Helix2 8 9 8
Strand1 21 21 21
Strand2 14 15 17
Turns 22 23 25
Unordered 21 16 12
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Fig. 4. Circular dichroism (CD) spectra of three immunogens with representative secondary structures. (A). CD spectra of OD1, OD2, and OD3 were measured at pH 8.0 and at
20 C and between 180 and 260 nm wavelengths. (B). The data was analyzed by software CDSSTR and is summarized in the table.
OD1 
1      2      3       4
OD2 
1      2      3       4
OD3 
1      2      3       4
Adjuvant 
1      2      3       4
25 KDa
120 KDa
Fig. 5. Western blotting analysis of antisera from immunized guinea pigs. Each serum from an individual animal in the test group was tested against its immunogen (OD1,
OD2 or OD3). As designed, there were four animals in each group. All antigen-immunized groups showed antibody-binding activity to gp120, but here only one is shown as a
positive control. All animals in the adjuvant only immunization group showed no antibody binding activity to OD1, OD2, OD3 and BSA (shown in Adjuvant 1, 2, 3, and 4
respectively).
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[25]. This is due to the lack of glycans on the proteins which were
produced in prokaryotic cells [33,34]. Although the VRC01 anti-
body, when bound to gp120, contacts the V5 loop, which is glyco-
sylated, the glycan is located at the outside part of loop and is not
actually involved in the binding [9].
Further characterization of the folding and conformation of the
OD1, OD2 and OD3 antigens was performed using Circular Dichro-
ism (CD) spectrophotometry. The data are shown in Fig. 4. It can be
seen obviously that the structural regions (a-helix, b-strand and
the turns) were increased from OD1(79%), OD2(84%) to OD3
(88%), and the unordered regions were reduced from OD1(21%),
OD2(16%) to OD3(12%). Therefore, the CD spectra indicates that
the OD3 has more ordered secondary structures than OD1 and
even OD2. This suggests that the OD3, which has the 375W is more
stabilized at the secondary structural level.
3.3. Immunogenicity test in guinea pigs
To evaluate the immunogenicity of OD3 and compare it to OD1
and OD2, we prepared the three antigens and immunized guinea
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Fig. 6. ELISA analysis of antibody titers (absorbance at 450 nm) in the antisera from immunized guinea pigs and their individual antigenic differences. (A). 96-well plates
were coated with three antigens, then were probed with dilutions of pre-bleed serum (Day 0), test bleed serum (Day 35), or final bleed serum (Day 63). Experiments were
performed in triplicate and figures represent an average data of multiple experiments. Upper four panels, serum dilution rate 1:100. Lower four panels, serum dilution rate
1:500. The pre-bleed, test bleed and final bleed antibody titers were compared in four groups (4 animals per group) immunized with OD1, OD2, OD3 or ADJ (adjuvant only).
(B). ELISA analysis of antisera from immunized guinea pigs comparing both the antigenic differences among three immunogens with the control group ADJ, and the antigenic
differences between OD1 and OD3 or OD2 and OD3. The sera from Day 35 (Test bleed group) and Day 63 (Final bleed group) were both tested.
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pigs at the same time so that a side-by-side comparison could be
achieved. The sample groups of OD1, OD2 and OD3 were injected
with immunogen and the adjuvant, but the control group was only
injected with the adjuvant and no immunogen. Antisera were col-
lected from all immunized guinea pigs at Day 0 (pre-bleed), on Day
35 (test bleed) and on Day 63 (final bleed). The details of the gui-
nea pig immunization are described in the methods section.
The antisera from the animals were tested by Western blotting
to check whether the outer domain immunogens raised specific
antibodies to the immunized antigens. The results were positive
and are shown in Fig. 5. All antisera from the animals of the
OD1, OD2 and OD3 groups had antibodies against the correspond-
ing antigens, but in the adjuvant group, all four animals were neg-
ative against the gp120 antigen (Fig. 5). The minor weaker
unspecific bands in the Patient sera and VRC01 gels are assumed
to be dimers or trimers.
The antibody titers in each animal were measured by Enzyme-
linked immunosorbent assay (ELISA), and the data are shown in
Fig. 6A, (also see Fig. S1). It is clear that the antibody titers have sig-
nificantly increased from the time post-immunization at Day 0
(pre-bleed) to Day 35 (test bleed) and Day 63 (final bleed). In gen-
eral, there were not significant differences in antibody titers
among the animals in each group, except for one animal in OD3
group which seemed to have responded poorly (Fig. 6A). These
antibody response data suggest that the outer-domain antigens
induced the animals’ immune responses and elicited specific anti-
bodies against these antigens. The average antibody titers from
each immunization group showed that OD3 was higher than
groups OD1 and OD2 on Day 35 or Day 63 (Fig. 6B). This suggests
that the OD3 immunogen was more immunogenic than OD1 and
OD2, although one animal had a poorer response to the OD3
immunogen. The data shows that OD3 animals still showed better
immune responses in general.
To further evaluate whether these antibodies produced by the
animals have neutralizing activities against HIV infection, a panel
of HIV-1 strains were tested which included a Tier 1 strain virus
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Fig. 7. Virus neutralization assays of antisera from immunized guinea pigs and comparisons of the neutralizing activities of three immunogens (OD1, OD2 and OD3). (A). To
compare the biological activity of the virus-specific neutralizing antibodies in guinea pig serum induced by the designed antigen OD3 with OD1, OD2 and ADJ, at different
serum dilution rates. Day 63 final bleed serum were used in this study. Each panel represents their activities against 6 different HIV-1 isolates: 89.6 (dual tropic virus), ADA
(R5 virus), HXBc2 (X4 virus), YU2 (X5 virus), 1084i (sub-type C R5 virus), JRFL (R5 virus). (B). Virus neutralization assay of antisera from OD3-immunized guinea pigs
comparing serum neutralizing activities against diverse HIV-1 isolates and a non-HIV-1 isolate. This figure compares the neutralizing activity of OD3-immunized serum in six
HIV-1 isolates, and one non-HIV-1 virus strain AMLV (Amphotropic Murine Leukemia Virus) serving as a negative control.
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(HXBc2) and several Tier 2 strain viruses (89.6, ADA, YU2, JRFL,
1084i) [35]. The neutralization results evidently showed that the
serum from animals who received the immunogen OD3 was more
effective than OD2 or OD1, and the neutralization activity
increased from Day 35 (test bleed) to Day 63 (final bleed) signifi-
cantly (Fig. 7A). More detailed virus neutralization data have been
presented in supplemental Figs. S2 and S3. All these data suggest
that more neutralizing antibodies were produced from the more
stabilized immunogen OD3 at Day 35 and 63. If we summarize
the immunization data from the final bleeds and compare their
antibody titers (1:100) and the neutralization activities (1:60),
we can conclude that the OD3 apparently is a better immunogen
than OD2 and OD1 (Table 2). We can also see that in Table 2, the
antibody titers did not significantly increase from OD1 to OD2
and OD3, but the virus neutralizing activities were largely
increased, some of them even having a two, three or four times
increase, as with the strains 89.6 and YU2. This implies that
immunogen stabilization has increased the elicitation of specific
neutralizing antibodies against HIV.
Finally, we examined whether these antibodies specifically neu-
tralized HIV. A non-HIV, but similar retrovirus, AMLV (Amphotro-
pic murine leukemia virus) was used as a control. The results
showed that several HIV-1 strains, JRFL, YU2, ADA, HXBc2 and
89.6 and including the subtype C strain 1084i were neutralized
by immunized guinea pig antisera, but AMLV was not neutralized
even at a 1:20 dilution (Fig. 7B). This suggests that the antibodies
in the sera were specific against HIV viruses. The non-HIV-1 AMLV
served as a negative control, reflecting that the neutralizing anti-
bodies are HIV-1 specific since they did not neutralize AMLV.
Among these HIV-1 isolates, the dual-tropic 89.6 seemed the most
vulnerable strain to OD3-induced antibody neutralization, fol-
lowed by the lab-adapted strain HXBc2.
4. Discussion
This research has shown the Phe-43 cavity filling residue 375W
can further stabilize the outer-domain core structure of gp120 into
the CD4-bound conformation in addition to the base of the stabi-
lization facilitated by the two-disulfide bond. The stabilized
outer-domain core clearly showed a significant improvement in
the immune response through the immunization of guinea pigs.
The neutralization activities against a variety of the HIV-1 isolates
have shown the potency and broad coverage of the induced anti-
bodies. We have noticed that the sera from OD3 immunization
seem to have weaker neutralizing activity against the subtype C
strain 1084i than other strains. We do not know why this autolo-
gous strain is more difficult to neutralize. Further investigations
are needed to find the mechanisms, which are also useful for future
antigen design.
This work again demonstrates that the CD4-BS of gp120 is an
important region for antibody targeting, and the CD4-binding por-
tion of the outer-domain appears to be even more imperative for
antibody targeting. As has been documented, potent neutralizing
antibodies such as VRC01 and PG04 are examples of targeting to
this region. If we compare the whole gp120 to the outer-domain
core as vaccine candidates, it is obvious that the outer-domain core
has advantages in terms of molecular size, stability and epitope
focusing. The outer-domain core structure avoids the unstable
inner domain and the flexible loops which reduces the unwanted
immunogenic face of the inner domain and focuses on the stable
epitopes of VRC01-like antibodies. Therefore, we can see the out-
comes of immunization data on the previous tested OD2 [18]
and this research on OD3. It is possible that more specific neutral-
izing antibodies might be raised but less total antibodies were pro-
duced which suggests that non-neutralizing antibodies were
reduced in the immunizations with OD2 and OD3. Based on this
set of immunization data with OD1, OD2 and OD3, we can clearly
see that the structure-based immunogen design has more rationale
and accuracy for inducing specific neutralizing antibodies, which
can be essentially explained by the epitope structural relationship
between antigens and antibodies. We will continue to pursue this
through investigations which purify the antibodies elicited from
these immunizations. Then, we will examine their structures, bind-
ing epitopes and affinity, and compare to the known reference
antibodies such as VRC01 and PG04. Thus, we may be able to gain
more insights into the use of structure-based approaches to design
more effective immunogens for HIV/AIDS vaccine development.
5. Conclusions
From these outer-domain structure-based immunogens, we can
conclude that the stabilized outer-domain in a CD4-bound confor-
mation elicits a better immune response than the un-stabilized
conformation. The stabilized outer-domain core could serve as a
better vaccine candidate in HIV vaccine development. In terms of
approach, the structure-based immunogen design has a rational
advantage and is demonstrated to be a good approach in this field.
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